YMTracker DRIPCalc v2 Launch sale

NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

XERS | NASDAQ

$9.98 $0.15 | 1.53%

SIGNAL:

Signal available — unlock to view

|2026-09-22 |F&G 58 |RSI 73.2

Add to favoritesFavorite

Company Overview:

Market Cap: $1.72B

Trailing PE: N/A

FWD PE *: 49.6x

Payout Ratio (TTM): —

52-Week Range: $5.25 - $11.33

* Forward PE is based on street estimates.

8.3 Year XERS Performance Metrics:

Total Return (with DRIP): -50.6% (-8.16% CAGR)

Total Return (no DRIP): -50.6% (-8.16% CAGR)

Share Price: -50.6% (-8.16% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $4,936

Total Return $ (with DRIP): -$5,064

XERS Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

XERS Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

XERS Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

XERS - Revenue

XERS Revenue CAGR:1Y: 28.74%2Y: 38.43%5Y: 59.56%10Y: 0.00%

XERS - Earnings Per Share (EPS)

XERS EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Net Income

🔓 See the full chart40% off right now · 7-day free trial

XERS Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

XERS EBITDA CAGR:1Y: 14.48%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

XERS Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

XERS Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

XERS Operating Income CAGR:1Y: 15.42%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

XERS Gross Profit CAGR:1Y: 39.80%2Y: 45.56%5Y: 70.50%10Y: 0.00%

XERS - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

XERS Shares Outstanding CAGR:1Y: 10.80%2Y: 7.94%5Y: 21.10%10Y: 0.00%

XERS - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

XERS Share Buybacks CAGR:1Y: -77.79%2Y: 93.52%5Y: 0.00%10Y: 0.00%

XERS - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

XERS Stock-Based Comp CAGR:1Y: 120.97%2Y: 61.69%5Y: 34.52%10Y: 0.00%

XERS - Expenses

🔓 See the full chart40% off right now · 7-day free trial

XERS Expenses CAGR:1Y: -25.09%2Y: -27.44%5Y: -0.84%10Y: 0.00%

XERS - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

XERS - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

XERS - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

XERS - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

XERS - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

XERS - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

XERS - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

XERS Revenue CAGR:1Y: 28.74%2Y: 38.43%5Y: 59.56%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

XERS - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

XERS Actual Revenue CAGR:1Y: 28.74%2Y: 38.43%5Y: 59.56%10Y: 0.00%

XERS - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

XERS Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

XERS Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

XERS Actual EBITDA CAGR:1Y: 14.48%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

XERS - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

XERS Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

XERS Gross Profit Margin CAGR:1Y: 8.58%2Y: 5.15%5Y: 6.86%10Y: 0.00%

XERS - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

XERS Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

XERS Price To Sales Ratio CAGR:1Y: 45.96%2Y: 48.96%5Y: -13.30%10Y: 0.00%

XERS - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

XERS Return on Capital Employed CAGR:1Y: 24.33%2Y: 0.00%5Y: 0.00%10Y: 0.00%

XERS - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

XERS Return on Invested Capital CAGR:1Y: -3.04%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for XERS

Based on past 8.3-year performance, here are XERS growth metrics:

Share price CAGR of -8.16%
Dividend CAGR of +0%

Using XERS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	XERS (DRIP)	XERS - No DRIP
Current Price	$9.98	$9.98
Start Shares	1,002.00	1,002.00
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,002.00	1,002.00
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$4.26	$9.98
Total Dividends	$0	$0
Final Value	$4,271	$10,000

Estimated Future Value + Dividends - XERS

NOTE: Above numbers are our estimate based on XERS's Dividend and Price CAGR over past 8.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

Xeris Biopharma Holdings, Inc. (XERS) had its IPO on 2018-06-21, and is traded on NASDAQ stock exchange.

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.

XERS website: https://www.xerispharma.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — XERS

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $9.98

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own XERS? See every dividend it's paid you

Add your XERS shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every XERS dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my XERS payments →

Free plan · up to 5 holdings